American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1Lauren A. Henderson, Jay Mehta, Kevin G. Friedman et al.|Arthritis & Rheumatology|2020Cited by 537
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2Lauren A. Henderson, Jay Mehta, Scott Canna et al.|Arthritis & Rheumatology|2020Cited by 415
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 3Lauren A. Henderson, Jay Mehta, Scott Canna et al.|Arthritis & Rheumatology|2022Cited by 297
A20: Understanding the Use and Biology of TNF Therapy in JIA—Clinical OutcomesDaniel J. Lovell, Edward H. Giannini, Timothy Beukelman et al.|Arthritis & Rheumatology|2014Cited by 1
A44: High Levels of DEK Autoantibodies May Predict Early Flare Following Cessation of Anti‐TNF TherapyNirit Mor‐Vaknin, David M. Markovitz, Miguel Rivas et al.|Arthritis & Rheumatology|2014Cited by 1